Colonic cancer secondary to radiation therapy : dose-response relationships and genetic changes.

继发于放射治疗的结肠癌：剂量反应关系和遗传变化。

• 批准号: 07671039
• 负责人: KATO Yo
• 金额: $ 1.34万
• 依托单位: Japanese Foundation for Cancer Research
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for Scientific Research (C)
• 财政年份: 1995
• 资助国家: 日本
• 起止时间: 1995 至 1996
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-07671039/
• 关键词: Colorectal carcinoma; Radiation therapy; Secondary cancer; Radiation proctitis; 放射性発癌; 晩発影響; 医療被曝

From 1946 to 1990,2909 cases of colorectal cancer were surgically treated. Twenty-nine (1%) of these had history of intrapelvic radiation for malignancy such as uterine cancer. The mean interval from the end of radiotherapy to the resection of colorectal cancer was 17 years and 5 months (range : 2 years 6 months to 35 years). Histologically, of 29 cases and 30 lesions, there were 3 cases (10%) of very well differentiated adenocarcinoma, 19 (63%) of well to moderately differentiated adenocarcinoma, 7 (24%) of mucinous carcinoma (MUC), and 1 (! %) of squamous cell carcinoma. The five year survival rate was 68%. For MUC alone, it was 100% (for MUC without radiotherapy, 33%). The 24% incidence of MUC in this series is higher than that (5%) of a general population. The longer the radiotherapy-to-resection interval, the more frequent the incidence of MUC as well as of radiation proctitis (19 cases). Associated with radiation proctitis were adenoma (5 cases), dysplasia (5 cases) and colitis cystica profunda (7 cases). We hypothesize that MUC in this series stems largely from radiation proctitis.

1946 ~ 1990年共手术治疗结直肠癌2909例。其中29例（1%）有恶性肿瘤（如子宫癌）盆腔内放疗史。从放疗结束到结直肠癌切除的平均时间为17年5个月（范围：2年6个月至35年）。组织学上，29例30个病灶中，极高分化腺癌3例（10%），高至中分化腺癌19例（63%），粘液癌（MUC）7例（24%），%）的鳞状细胞癌。5年生存率为68%。对于单独的MUC，其为100%（对于MUC未进行放射治疗，为33%）。该系列中MUC的发病率为24%，高于一般人群的发病率（5%）。放疗至切除间隔时间越长，MUC和放射性直肠炎的发生率越高（19例）。伴发放射性直肠炎的有腺瘤5例，异型增生5例，深部囊性结肠炎7例。我们推测，MUC在这一系列的根源主要是放射性直肠炎。

项目成果

Abe T.,Ouyang H.,Migita T,Kato Y.,Kimura M.,et.al.: "The somatic mutation frequency of the transforming growth factor β recepter type II gene varies widely among different cancers with micro-satellite instability." European Journal of Surgical Oncology. 2

Abe T.、Ouyang H.、Migita T、Kato Y.、Kimura M.等人：“转化生长因子β受体 II 型基因的体细胞突变频率在具有微卫星不稳定性的不同癌症中差异很大。 “欧洲肿瘤外科杂志。2